[go: up one dir, main page]

CL2008003582A1 - Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash). - Google Patents

Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash).

Info

Publication number
CL2008003582A1
CL2008003582A1 CL2008003582A CL2008003582A CL2008003582A1 CL 2008003582 A1 CL2008003582 A1 CL 2008003582A1 CL 2008003582 A CL2008003582 A CL 2008003582A CL 2008003582 A CL2008003582 A CL 2008003582A CL 2008003582 A1 CL2008003582 A1 CL 2008003582A1
Authority
CL
Chile
Prior art keywords
nafld
cystamine
nash
alcoholic
preparation
Prior art date
Application number
CL2008003582A
Other languages
English (en)
Inventor
Ranjan Dohil
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003582(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of CL2008003582A1 publication Critical patent/CL2008003582A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso de un producto de cisteamina para preparar un medicamento para tratar hígado graso.
CL2008003582A 2007-11-30 2008-12-01 Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash). CL2008003582A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99151707P 2007-11-30 2007-11-30
US8539708P 2008-07-31 2008-07-31

Publications (1)

Publication Number Publication Date
CL2008003582A1 true CL2008003582A1 (es) 2009-04-03

Family

ID=40679016

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003582A CL2008003582A1 (es) 2007-11-30 2008-12-01 Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash).

Country Status (25)

Country Link
US (5) US7994226B2 (es)
EP (2) EP2636404B1 (es)
JP (3) JP5583022B2 (es)
KR (1) KR20100091219A (es)
CN (2) CN104825430B (es)
AR (1) AR069500A1 (es)
AU (1) AU2008329628B2 (es)
BR (1) BRPI0819690B8 (es)
CA (1) CA2706768C (es)
CL (1) CL2008003582A1 (es)
CY (1) CY1114126T1 (es)
DK (1) DK2214480T3 (es)
ES (1) ES2417179T3 (es)
HR (1) HRP20130590T1 (es)
IL (2) IL205909B (es)
MX (2) MX360827B (es)
MY (1) MY156316A (es)
NZ (1) NZ585732A (es)
PL (1) PL2214480T3 (es)
PT (1) PT2214480E (es)
RU (1) RU2498795C2 (es)
SG (1) SG10201403200RA (es)
TW (2) TWI535435B (es)
WO (1) WO2009070781A1 (es)
ZA (1) ZA201003670B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2535044T1 (sl) 2006-01-27 2020-06-30 The Regents Of The University Of California Cisteamin bitartrat in cistamin z enterično oblogo
EP2636404B1 (en) 2007-11-30 2019-03-20 The Regents of The University of California Methods of Treating Non-Alcoholic Steatohepatitis (Nash) Using Cysteamine Products
JP5800368B2 (ja) * 2010-05-19 2015-10-28 興和株式会社 非アルコール性脂肪性肝炎の予防及び／又は治療剤
CA2801336C (en) * 2010-06-08 2020-01-28 Mahesh Kandula Cysteamine derivatives and their use in the treatment of nash
ES2565487T3 (es) * 2010-07-28 2016-04-05 Orchid Chemicals And Pharmaceuticals Ltd Compuestos de difeniléter para su uso en el tratamiento de enfermedades hepáticas
WO2014045293A1 (en) * 2012-09-24 2014-03-27 Krisani Bioscience (P) Ltd. Fatty acid amides with a cysteamine or an acetylated cysteamine group and uses thereof
US20130085075A1 (en) * 2011-06-06 2013-04-04 Meso Scale Technologies, Llc Diagnostic methods for liver disorders
MX360979B (es) * 2011-09-16 2018-11-22 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico.
MX2014004994A (es) * 2011-10-26 2014-08-27 Seattle Children S Res Inst Cisteamina en el tratamiento de enfermedad fibrotica.
BR112014012167A2 (pt) * 2011-11-22 2017-05-30 The Regents Of The Univ Of Calefornia métodos para tratar um indivíduo, um evento isquêmico, métodos para aumentar a razão de níveis de adiponectina e os níveis de adiponectina, e, cisteamina, derivado de cisteamina, derivado de cistamina
US20150086627A1 (en) * 2012-03-29 2015-03-26 Halo Therapeutics, Llc. Dosage forms of halofuginone and methods of use
EP2858651B1 (en) 2012-06-06 2020-11-11 Galectin Therapeutics Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
US20140314841A1 (en) 2013-04-19 2014-10-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases
TWI649100B (zh) * 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
JP6490097B2 (ja) * 2014-04-18 2019-03-27 エルジー・ケム・リミテッド 脂肪肝疾患の予防又は治療用組成物
AU2016226906B2 (en) * 2015-03-03 2021-06-10 KOHJIN Life Sciences Co., Ltd. Composition for improving or preventing nonalcoholic fatty liver
AU2016288230A1 (en) 2015-07-02 2018-01-25 Horizon Orphan Llc ADO-resistant cysteamine analogs and uses thereof
RU2595815C1 (ru) * 2015-07-13 2016-08-27 федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохранения Российской Федерации Способ лечения больных неалкогольным стеатогепатитом на фоне метаболического синдрома
WO2017087532A1 (en) * 2015-11-16 2017-05-26 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
KR102414503B1 (ko) * 2016-03-17 2022-06-29 티오제네시스 테라퓨틱스, 인크. 시스테아민의 조절 방출을 위한 조성물 및 시스테아민 민감성 장애의 전신 치료
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
PT3634411T (pt) * 2017-06-08 2023-11-28 N Gene Res Laboratories Inc Métodos para o tratamento de nash e para a prevenção de hcc induzido por nash
WO2019046659A1 (en) * 2017-08-30 2019-03-07 First Fruits Business Ministry, Llc COMPOSITION AND METHOD FOR INCREASING SERIAL ADIPONECTIN AND REDUCING THE LIPID RESERVES OF THE ORGANISM
CN118924717A (zh) 2017-09-20 2024-11-12 硫创治疗公司 用于治疗半胱胺敏感性病症的方法
KR102177304B1 (ko) * 2018-07-23 2020-11-10 제이투에이치바이오텍 (주) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
CN111544426A (zh) * 2019-02-12 2020-08-18 复旦大学 炔丙基半胱氨酸及其在制备新靶点药物中的用途
EP3946298A4 (en) * 2019-03-26 2023-01-25 The Regents of the University of California Substituted amino-thiol and amino-disulfide compounds, and uses thereof
CA3143834A1 (en) * 2019-07-19 2021-01-28 Xiyan LI Compositions, methods, kits and systems for cancer treatment and metabolic intervention therapy and other uses
CN111505099B (zh) * 2020-04-21 2023-07-04 上海市普陀区中心医院 Nash的诊断标志物及其应用
WO2022128870A1 (en) * 2020-12-18 2022-06-23 Société des Produits Nestlé S.A. Compositions and methods using at least one glycine or derivative thereof and/or at least one n-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol
CN118489805A (zh) * 2024-05-31 2024-08-16 杭州康德权饲料有限公司 半胱胺或其盐在制备预防和改善蛋鸡脂肪肝的饲料添加剂中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110441A (en) * 1974-04-29 1978-08-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Gamma-l-glutamyl cholamine phosphate
US4959306A (en) * 1986-11-28 1990-09-25 Sclavo, Inc. Labeling design for a binding assay reagent
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5639743A (en) * 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
JPH11302178A (ja) * 1998-02-17 1999-11-02 Otsuka Pharmaceut Factory Inc 脂肪肝予防及び治療剤
CA2236344A1 (en) 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
US20050059576A1 (en) * 1998-04-30 2005-03-17 Adamson J. Gordon Targeted delivery of antiviral compounds through hemoglobin bioconjugates
US6794414B1 (en) 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
WO2001058708A1 (en) * 2000-02-14 2001-08-16 Len Booysen Stabilizer unit
CN1144585C (zh) 2000-12-13 2004-04-07 华扩达动物科学[I.P.2]有限公司 含有半胱胺或其盐类的促进动物快速生长的组合物及用途
US7449451B2 (en) 2001-08-29 2008-11-11 Premier Micronutrient Corporation Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
GB2379854B (en) 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
CN1596111A (zh) 2001-11-29 2005-03-16 桑得医药品公司 减轻化疗引起的不良效果的组合物及方法
CA2825792C (en) 2002-01-04 2016-08-16 Sound Pharmaceuticals Incorporated Otoprotectant compositions of glutathione peroxidase mimics for ameliorating hearing loss
GB2386817B (en) 2002-02-20 2006-08-23 Walcom Animal Science Feed for fish and use therof
JP2004026716A (ja) 2002-06-25 2004-01-29 Ajinomoto Co Inc ＴＮＦα産生の抑制剤
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
GB2398497A (en) 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
JP4966665B2 (ja) * 2003-11-19 2012-07-04 オメガ バイオ−ファーマ （アイ．ピー．１） リミテッド アルコール代謝を改善し、二日酔いの影響を軽減するための材料と方法
ATE515261T1 (de) 2003-12-19 2011-07-15 Omega Bio Pharma Ip3 Ltd Zusammensetzungen zur behandlung von diabetes
WO2005092914A1 (en) * 2004-03-22 2005-10-06 Blue Mountain Technology Development Lab Process for promoting proper folding of human serum albumin using a human serum albumin ligand
EP1744737A2 (en) * 2004-05-03 2007-01-24 Omega Bio-Pharma (I.P.3) Limited Cysteamines for treating complications of hypercholesterolemia and diabetes
BRPI0519606A2 (pt) 2005-01-05 2009-02-25 Abdalla Magd Ahmed Kotb sÍntese, produÇço e utilidade da taurina como um remÉdio
BRPI0607531A2 (pt) 2005-04-20 2009-09-15 Hutchinson Fred Cancer Res métodos, composições e artigos de fabricação para intensificação da capacidade de sobrevivência de células, tecidos, órgãos e organismos
JP2009521452A (ja) * 2005-12-21 2009-06-04 シェーリング コーポレイション コレステロール降下剤およびｈ３受容体アンタゴニスト／逆アゴニストを使用する非アルコール性脂肪性肝疾患の処置
US20070172514A1 (en) 2006-01-20 2007-07-26 Francis Chi Materials and methods for improving livestock productivity
SI2535044T1 (sl) * 2006-01-27 2020-06-30 The Regents Of The University Of California Cisteamin bitartrat in cistamin z enterično oblogo
WO2007121545A1 (en) * 2006-04-20 2007-11-01 Universidade Estadual De Campinas-Unicamp S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
US20090304704A1 (en) 2006-05-03 2009-12-10 Geisinger Clinic Methods for diagnosing and predicting non-alcoholic steatohepatitis (nash)
WO2008093764A1 (ja) 2007-02-02 2008-08-07 Kaneka Corporation 糖尿病予防または治療用組成物
EP2636404B1 (en) * 2007-11-30 2019-03-20 The Regents of The University of California Methods of Treating Non-Alcoholic Steatohepatitis (Nash) Using Cysteamine Products

Also Published As

Publication number Publication date
DK2214480T3 (da) 2013-07-08
TWI478710B (zh) 2015-04-01
SG10201403200RA (en) 2014-10-30
US10307386B2 (en) 2019-06-04
BRPI0819690B8 (pt) 2021-05-25
EP2636404A2 (en) 2013-09-11
CN101932238B (zh) 2015-04-08
CY1114126T1 (el) 2016-07-27
KR20100091219A (ko) 2010-08-18
BRPI0819690B1 (pt) 2019-07-30
US20130183351A1 (en) 2013-07-18
AU2008329628A1 (en) 2009-06-04
CA2706768C (en) 2016-06-28
TW200927093A (en) 2009-07-01
IL205909A0 (en) 2010-11-30
JP6121951B2 (ja) 2017-04-26
CN104825430A (zh) 2015-08-12
CN104825430B (zh) 2018-05-04
RU2498795C2 (ru) 2013-11-20
EP2636404A3 (en) 2013-10-16
ES2417179T3 (es) 2013-08-06
US7994226B2 (en) 2011-08-09
BRPI0819690A2 (pt) 2014-10-07
HK1141945A1 (en) 2010-11-26
US9511038B2 (en) 2016-12-06
TWI535435B (zh) 2016-06-01
ZA201003670B (en) 2011-08-31
US20100303870A1 (en) 2010-12-02
PT2214480E (pt) 2013-07-23
US8263662B2 (en) 2012-09-11
EP2636404B1 (en) 2019-03-20
EP2214480B1 (en) 2013-03-27
US20160143865A1 (en) 2016-05-26
MX2010005921A (es) 2010-06-11
JP5583022B2 (ja) 2014-09-03
PL2214480T3 (pl) 2013-11-29
EP2214480A1 (en) 2010-08-11
CA2706768A1 (en) 2009-06-04
MX360827B (es) 2018-11-16
JP2014237670A (ja) 2014-12-18
US9149448B2 (en) 2015-10-06
AU2008329628B2 (en) 2014-06-26
NZ585732A (en) 2012-02-24
JP2017165735A (ja) 2017-09-21
HRP20130590T1 (en) 2013-08-31
US20170304233A1 (en) 2017-10-26
WO2009070781A1 (en) 2009-06-04
IL205909B (en) 2018-05-31
RU2010126631A (ru) 2012-01-10
EP2214480A4 (en) 2010-09-29
IL254586A0 (en) 2017-11-30
CN101932238A (zh) 2010-12-29
MY156316A (en) 2016-02-11
US20120015005A1 (en) 2012-01-19
JP2011505375A (ja) 2011-02-24
TW201513855A (zh) 2015-04-16
AR069500A1 (es) 2010-01-27

Similar Documents

Publication Publication Date Title
CL2008003582A1 (es) Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash).
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
BRPI0906181A2 (pt) &#34;método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer&#34;
CL2018001007A1 (es) Composiciones farmacéuticas para terapias combinadas (sol. divisional de n° 201702538).
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
BR112012010706A2 (pt) composto, composição farmacêutica, combinação do produto farmacêutico, uso de um composto, e, métodos para o tratamento de uma doença ou condição, e para inibir um bromodomínio
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
BR112014032526A2 (pt) composto, e composição farmacêutica
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
CL2008001002A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
BRPI0517701A (pt) uso de um composto na preparação de medicamentos para o tratamento de diabetes mellitus
CL2008001003A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
CL2010001260A1 (es) Composicion farmaceutica que comprende una sal de estroncio y vitamina d y una ciclodextrina, donde la relacion masica entre la cantidad de vitamina d y la cantidad de ciclodextrina esta comprendida entre 1/40 y 1/800, util para tratar o prevenir osteoporosis.
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol &gt; 0,75 y 1
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
MX2009002054A (es) Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis.
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
GT200800235A (es) Formulacion de medicamento liquida
PE20120956A1 (es) Composicion farmaceutica que contiene buprenorfina y nalmefeno
CL2011001777A1 (es) Composicion farmaceutica que contiene aleglitazar; proceso para preparar dicha composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes tipo ii o enfermedades cardiovasculares.
BRPI1011851A2 (pt) Composto, composição farmacêutica, e, métodos para induzir apoptose em uma célula, epara tratar uma doença
AR066670A1 (es) Concentrado de esmolol
AR062248A1 (es) Composiciones y metodos para tratar artritis reumatoidea